Skip to main content

Table 2 Antiviral therapy related outcomes of the participants, by study arm

From: Effect of a multi-dimensional case management model on anti-retroviral therapy-related outcomes among people living with human immunodeficiency virus in Beijing, China

Indicator

All Participants

Participants with CD4 Less Than 350/μL

Control group (n = 1549)

Intervention group (n = 3357)

P-value

Control group (n = 1158)

Intervention group (n = 1983)

P-value

Virological failure

60 (3.9)

31 (0.9)

< 0.001

51 (4.4)

27 (1.4)

< 0.001

Retention in care

1466 (94.6)

3159 (94.1)

0.449

1096 (94.6)

1774 (93.7)

0.290

pre-treatment interval (days)1

56 (26–253)

35 (18–133)

< 0.001

48 (25–252)

35 (17–106)

< 0.001

Good ART adherence

1381 (89.2)

3199 (95.3)

< 0.001

949 (82.0)

1817 (96.0)

< 0.001

Death (/per 100 year)

11 (0.4)

10 (0.2)

< 0.001

11 (0.9)

10 (0.5)

< 0.001

  1. 1pre-treatment interval, days from when a participant tested positive for HIV using a Western Blot test to when he/she initiated treatment